

KEY STATISTICS

Shares Outstanding: 30.92M
Share Price: (12.6.13): \$0.71
Average Volume (3m): 105,909

Revenue Growth (MRQ): 51.5%
Net Income (MRQ): \$28,313

BUSINESS OVERVIEW

Arrayit Corporation develops, manufactures and markets a comprehensive line of microarray life science tools and integrated systems for the large-scale analysis of genetic variation and biological function. The Company's leading-edge microarray technology advances basic research globally in academic institutions; government and private laboratories; genomic research centers; and pharmaceutical, diagnostic, and biotechnology companies. The Company has also leveraged its proprietary and patented microarray platform to develop a wide range of diagnostic testing solutions for which it is preparing to submit FDA 510(k) applications.

COMPANY HIGHLIGHTS

Trend Toward Personalized Medicine

- Arrayit stands at the center of this trend which is revolutionizing modern medicine by customizing treatment to a patient's molecular and genetic profile
- Tools and diagnostics business both stand to benefit

Attractive Business Model

- Opportunity for sustained profitability (GAAP profitable for first nine months of 2013)
- 30+% of revenues are high margin consumables
- Large NOL

Large and Growing Microarray Market

- Microarray market forecasted by ResearchMoz to grow 18.6% CAGR
- US \$11.4B market by 2018

Microarray Pioneer and Innovator

- Dr. Mark Schena, PhD is a leading talent in scientific and technological innovation and the originator of Microarray Technology
- Patented and proprietary technology platform

Opportunity to Grow Diagnostic Testing Business

- Leverages core microarray business
- Preparing to submit FDA 510(k) application for OvaDx[®] Ovarian Cancer Monitoring Test

TOOLS AND SYSTEMS

Custom Printing Equipment



- Patented, high speed
- Proprietary contact printing technology
- Print all sample types

Slides/Reagents (Consumables)




- High margin
- 30%+ of revenues
- Optimized for use with Arrayit instruments

Detection (Scanners)



- Colorimetric and fluorescence detection
- Highest speed and resolution on market

Analysis (Software)



- Advanced quantification and analysis software
- Large number of patient samples
- Oncology, neurodegenerative disease and lifestyle

DIAGNOSTICS OPPORTUNITY

- Microarray is a core technology for many diagnostic tests
- Large market opportunity: underserved and widespread applications
- Extensive pre-application testing
Company well-positioned for 510(k) applications

OVADx® SCREENING TEST

Need for Ovarian Cancer Screening Test

- Ovarian cancer 5th leading cause of cancer death among American women
- Symptoms are subtle and ambiguous
- Early detection is key for increased survival rate

OvaDx® Ovarian Cancer Test

- Improved monitoring and early detection
- 5-year survival rate could improve from 20% to 80%
- Preventative procedure typically does not require chemotherapy or radiation therapy
- Affordable cost
- Industry-leading sensitivity and specificity
- Preparing to submit 510(k) application

GROWTH STRATEGY

Tools and Integrated Systems

- Continue to **drive product innovation** utilizing patented contact printing technology
- **Broaden international distribution** base
- Increase direct sales through **e-commerce** expertise
- Focus on **increasing sales of consumables** to installed instruments customer base
- Strategic M&A

Diagnostics

- Submit 510(k) application for OvaDx®
- Pursue additional longer term opportunities in the diagnostics space that leverage company's technology

Company Contact:

Mark Schena
President, Arrayit Corporation
(408) 744-1331

Investor Contact:

John Nesbett/Jennifer Belodeau
Institutional Marketing Services (IMS)
(203) 972-9200

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2012 and in Form 10-Q for the quarterly period ended September 30, 2013.